8AT Stock Chart & Stats
€3.36
-€0.01(-0.54%)
At close: 4:00 PM EST
€3.36
-€0.01(-0.54%)
Day’s Range― - ―
52-Week Range€1.28 - €4.94
Previous CloseN/A
Volume0.00
Average Volume (3M)880.00
Market Cap
€696.02M
Enterprise Value€379.61
Total Cash (Recent Filing)€105.42M
Total Debt (Recent Filing)€1.99M
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Aug 12, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding139,663,680
10 Day Avg. Volume0
30 Day Avg. Volume880
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.40Price Target Upside179.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.59
Revenue Forecast (FY)€5.00M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsAclaris reports very high gross margins in recent periods, indicating attractive unit economics for its therapies. Durable margin strength provides a structural cushion as the company scales, improving the potential for operating leverage once revenue growth supports fixed R&D and G&A costs.
Positive Phase 1a DataFirst-in-human Phase 1a results for ATI-052 showing a potentially best-in-class PK profile (dosing as infrequently as every three months) materially de-risks the program. Coupled with a defined lead indication for ATI-2138, this strengthens the pipeline and supports a clearer long-term clinical and commercial strategy.
Low Financial LeverageMinimal debt reduces fixed financing obligations and bankruptcy risk, giving the company flexibility to raise capital on favorable terms or pursue partnerships. Low leverage is a durable financial strength that supports continued R&D investment without immediate solvency pressure.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow (~-$52M TTM) means the business cannot self-fund development. Over the medium term this forces dependency on external financing or partnerships, increasing execution risk and the chance of program delays if capital access tightens.
Deep Operating LossesDespite high gross margins, operating losses are large relative to a small, volatile revenue base and returns on equity are persistently negative. This structural mismatch implies the current cost base and development spending are not supported by commercial cash flow, posing scaling and sustainability challenges.
Dilution Risk From FinancingThe company's reliance on equity financings to fund operations creates recurring dilution and equity volatility. Over time, repeated capital raises can erode per-share economics, complicate long-term shareholder returns, and may signal limited near-term ability to self-sustain development spend.
Aclaris Therapeutics News
8AT FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was €1.28 and its highest was €4.94 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is €696.02M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 20 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on May 12, 2026. The company reported -€0.131 earnings per share for the quarter, beating the consensus estimate of -€0.138 by €0.007.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 139,663,680 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -€0.131 in its last earnings report, beating expectations of -€0.138. Following the earnings report the stock price went up 0.434%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in DE:8AT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.40 (179.66% Upside)
€9.40 (179.66% Upside)
Insider Transactions
Sold Shares
Worth €1.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.32%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
8AT Stock 12 Month Forecast
Average Price Target
€9.40
▲(179.66% Upside)